Product Description
Sapanisertib is a dual TORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. These mutations are found in a considerable sub-population of patients across multiple solid tumor types. (Sourced from: https://www.calithera.com/mtorc1-2-inhibitor-sapanisertib-cb-228/)
Mechanisms of Action: mTOR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Lung Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Calithera Biosciences
Company Location: Western America
Company Founding Year: 2010
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, United Kingdom, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Carcinosarcoma|Clear Cell Adenocarcinoma|Clear Cell Sarcoma|Endometrial Cancer|Endometrioid Carcinoma|Fallopian Tube Cancer|Mixed Tumor, Mullerian|Ovarian Cancer|Peritoneal Cancer|Serous Cystadenocarcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06463028 |
FTH-PIK-201 | P2 |
Recruiting |
Endometrial Cancer |
2028-09-01 |
12% |
2025-06-05 |
Primary Endpoints |
NCT03648489 |
DICE | P2 |
Completed |
Ovarian Cancer|Endometrioid Carcinoma|Fallopian Tube Cancer|Peritoneal Cancer|Clear Cell Adenocarcinoma|Serous Cystadenocarcinoma|Carcinosarcoma|Mixed Tumor, Mullerian|Clear Cell Sarcoma |
2023-11-30 |
49% |
2024-09-21 |
Primary Endpoints |